Neoleukin Therapeutics Stock Price

0.29 (2.07%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Neoleukin Therapeutics Inc NLTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-3.01 -17.7% 14.00 14.00 14.9099 14.69 17.01 00:00:04
Bid Price Ask Price Spread Spread % News
14.00 19.30 5.30 27.46% 2 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
20,914 2,630,684 $ 14.34 $ 37,717,871 607,264 2.53 - 18.13
Last Trade Time Type Quantity Stock Price Currency
19:46:20 15 $ 14.29 USD

Neoleukin Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 538.79M 38.49M 32.37M $ - $ - -2.41 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Neoleukin Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NLTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week16.7217.5714.0015.731,240,079-2.72-16.27%
1 Month12.7018.1311.3515.24632,4201.3010.24%
3 Months10.8018.1310.2614.21367,7093.2029.63%
6 Months12.3218.135.8112.06365,6491.6813.64%
1 Year3.9818.132.5310.34349,06310.02251.76%
3 Years3.9818.132.5310.34349,06310.02251.76%
5 Years3.9818.132.5310.34349,06310.02251.76%

Neoleukin Therapeutics Description

Neoleukin Therapeutics Inc operates as a biopharmaceutical company. It generates immunotherapies using de novo protein design technology. The firm uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.

Your Recent History
Neoleukin ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.